title: [Ceftazidime: advantages of continuous infusions in a patient with aplasia].
authors.forename: O
authors.initials: O
authors.lastname: Legrand
authors.forename: J P
authors.initials: JP
authors.lastname: Marie
authors.forename: C
authors.initials: C
authors.lastname: Bardin
authors.forename: Y
authors.initials: Y
authors.lastname: Bezie
authors.forename: C
authors.initials: C
authors.lastname: Hermelin
authors.forename: J L
authors.initials: JL
authors.lastname: Herrmann
authors.forename: F
authors.initials: F
authors.lastname: Chast
authors.forename: R
authors.initials: R
authors.lastname: Zittoun
mesh_terms: D000741:Anemia, Aplastic / Q000150:complications*; D002442:Ceftazidime / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010000:Osteitis / Q000188:drug therapy; D011552:Pseudomonas Infections / Q000188:drug therapy
chemical_list: D002442:Ceftazidime
vernacular_title: Ceftazidime: avantages des perfusions continues chez un malade en aplasie.